financetom
Business
financetom
/
Business
/
Ralph Lauren Insider Sold Shares Worth $3,441,000, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Ralph Lauren Insider Sold Shares Worth $3,441,000, According to a Recent SEC Filing
Mar 25, 2025 1:23 PM

04:06 PM EDT, 03/25/2025 (MT Newswires) -- Patrice Louvet, Director, President and CEO, on March 24, 2025, sold 14,800 shares in Ralph Lauren ( RL ) for $3,441,000. Following the Form 4 filing with the SEC, Louvet has control over a total of 97,249 Class A common shares of the company, with 97,249 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1037038/000095014225000838/xslF345X05/es250608013_4-louvet.xml

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Baidu-backed Ji Yue Auto to streamline operations, seeks to raise fresh funds
Baidu-backed Ji Yue Auto to streamline operations, seeks to raise fresh funds
Dec 11, 2024
BEIJING, Dec 11 (Reuters) - Baidu ( BIDU ) and Geely's carmaking joint venture, Ji Yue said on Wednesday that it would seek to raise new money and carry out some operational adjustments to cope with fierce market competition. The electric car maker said on its social media account that it was looking to merge departments and positions that had...
Rocket Pharmaceuticals Prices Upsized $165 Million Stock Offering
Rocket Pharmaceuticals Prices Upsized $165 Million Stock Offering
Dec 11, 2024
08:50 AM EST, 12/11/2024 (MT Newswires) -- Rocket Pharmaceuticals ( RCKT ) said Wednesday that it has priced an upsized public offering of 13.2 million shares at $12.50 each, expected to raise $165 million in gross proceeds. The company said the offering, slated to close around Thursday, includes a 30-day option for underwriters to purchase an additional 1.98 million shares....
AnaptysBio to abandon eczema drug development after mid-stage trial failure
AnaptysBio to abandon eczema drug development after mid-stage trial failure
Dec 11, 2024
Dec 11 (Reuters) - AnaptysBio ( ANAB ) said on Wednesday it would end the development of its eczema drug after it failed to meet the main and secondary goals of a mid-stage trial. The company's shares were halted during premarket trade. The drug, ANB032, did not meet the primary goal of the proportion of patients who achieved at least...
Oil Rises on China Demand Hopes, Even as U.S. Inventories Rise and OPEC Trims Its Demand-Growth Forecast
Oil Rises on China Demand Hopes, Even as U.S. Inventories Rise and OPEC Trims Its Demand-Growth Forecast
Dec 11, 2024
08:49 AM EST, 12/11/2024 (MT Newswires) -- Oil prices rose early on Wednesday as China's decision on Monday to loosen monetary policy continues to support the commodity. The gains come even as OPEC lowered its demand forecast for this year and next and a report showed an unexpected rise in U.S. inventories. West Texas Intermediate crude for January delivery was...
Copyright 2023-2026 - www.financetom.com All Rights Reserved